This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Greatbatch, Inc. Reports 2011 Fourth Quarter And Full Year Results

Fourth quarter and full year 2011 Vascular Access sales increased 28% and 19%, respectively, over the prior year periods. These increases were primarily attributable to growth in the underlying market and market share gains. Additionally, Vascular Access revenue for the quarter included approximately $2 million ($4 million full year) from sales of medical devices that were developed under the Greatbatch name.

In comparison to the prior year, Orthopaedic product line sales increased 3% and 18%, respectively, for the fourth quarter and full year periods. Full year 2011 Orthopaedic sales included the favorable impact of approximately $8 million from foreign currency exchange rate fluctuations. Foreign currency exchange rate fluctuations did not have a material impact on fourth quarter revenue. On a constant currency basis, Orthopaedic sales for 2011 were up 11% over the prior year period. These increases were across substantially all of our product lines and were a direct result of the investments made over the last several years to expand capabilities, shorten lead times, and improve quality and on-time delivery.

Electrochem

Fourth quarter 2011 sales for the Electrochem business segment increased 44% in comparison to the prior year and were up 9% for the full year. Fourth quarter 2011 sales for Electrochem included $2.5 million of additional revenue from the Micro Power acquisition. Excluding the additional revenue provided by Micro Power, sales for the 2011 fourth quarter and full year increased 27% and 6%, respectively. During 2011, Electrochem revenue varied from quarter to quarter due to the timing of various customer inventory pulls. For the full year, the increase in Electrochem revenue was a result of an increased investment in sales and marketing, which resulted in market share gains and several new customer contracts, as well as continued strength in the energy markets.

Financial GuidanceFor 2012, Greatbatch estimates annual revenue growth rates for its product lines as follows:

CRM & Neuromodulation:     -3% to 0%
Vascular Access: 10% to 20%
Orthopaedic: 5% to 15%
Electrochem (1): Approximately 5%

(1) Percentage increase assuming full year pro forma Micro Power revenue in 2011.

6 of 9

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,033.60 -36.80 -0.20%
S&P 500 2,104.69 -9.80 -0.46%
NASDAQ 4,969.0050 -47.9240 -0.96%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs